Ishioka C, Osada M, Gamo M, Kanamaru R
Dept. of Clinical Oncology, Tohoku University, Sendai, Japan.
Gan To Kagaku Ryoho. 1997 Dec;24(15):2207-12.
Development of novel strategies is required for cancer treatment because most human tumors are refractory to current conventional therapy. During the past decade, a number of oncogenes and tumor suppressor genes have been cloned and the molecular mechanisms as to how mutations in such genes contribute to tumor development are going to be clarified. It is, therefore, a great challenge to develop novel strategies for tumor specific therapy based on molecular biology of cancer. p53 tumor suppressor gene is one of the most frequently mutated genes in a variety of human cancers. This review paper introduces several recent approaches related to the p53 as a molecular target of cancer treatment, including (i) p53 status and chemo-radiosensitivity, (ii) p53 gene therapy, (iii) E1B-deficient adenovirus and (iv) restoration of p53 function by synthetic polypeptides.
由于大多数人类肿瘤对当前的传统疗法具有抗性,因此癌症治疗需要开发新的策略。在过去十年中,许多癌基因和肿瘤抑制基因已被克隆,并且此类基因中的突变如何促进肿瘤发展的分子机制也将被阐明。因此,基于癌症分子生物学开发肿瘤特异性治疗的新策略是一项巨大的挑战。p53肿瘤抑制基因是多种人类癌症中最常发生突变的基因之一。这篇综述文章介绍了几种最近与作为癌症治疗分子靶点的p53相关的方法,包括(i)p53状态与放化疗敏感性,(ii)p53基因治疗,(iii)E1B缺陷型腺病毒,以及(iv)通过合成多肽恢复p53功能。